Katsuyuki Matsushita1, Kiyoshi Mori2, Turgay Saritas3,4, Mahaba B Eiwaz1, Yoshio Funahashi1, Megan N Nickerson1, Jessica F Hebert1, Adam C Munhall1, James A McCormick3, Motoko Yanagita5,6, Michael P Hutchens7,8. 1. Anesthesiology & Perioperative Medicine, Oregon Health & Science University, Portland, Oregon. 2. School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan. 3. Division of Nephrology & Hypertension, Oregon Health & Science University, Portland, Oregon. 4. Division of Nephrology & Hypertension, University Hospital RWTH Aachen, Aachen, Germany. 5. Department of Nephrology, Kyoto University Graduate School of Medicine, Kyoto, Japan. 6. Institute for Advanced Study of Human Biology, Kyoto University, Kyoto, Japan. 7. Anesthesiology & Perioperative Medicine, Oregon Health & Science University, Portland, Oregon hutchenm@ohsu.edu. 8. Portland Veterans Affairs Medical Center, Operative Care Division, Portland, Oregon.
Abstract
BACKGROUND: Rhabdomyolysis, the destruction of skeletal muscle, is a significant cause of AKI and death in the context of natural disaster and armed conflict. Rhabdomyolysis may also initiate CKD. Development of specific pharmacologic therapy is desirable because supportive care is nearly impossible in austere environments. Myoglobin, the principal cause of rhabdomyolysis-related AKI, undergoes megalin-mediated endocytosis in proximal tubule cells, a process that specifically injures these cells. METHODS: To investigate whether megalin is protective in a mouse model of rhabdomyolysis-induced AKI, we used male C57BL/6 mice and mice (14-32 weeks old) with proximal tubule-specific deletion of megalin. We used a well-characterized rhabdomyolysis model, injection of 50% glycerol in normal saline preceded by water deprivation. RESULTS: Inducible proximal tubule-specific deletion of megalin was highly protective in this mouse model of rhabdomyolysis-induced AKI. The megalin knockout mice demonstrated preserved GFR, reduced proximal tubule injury (as indicated by kidney injury molecule-1), and reduced renal apoptosis 24 hours after injury. These effects were accompanied by increased urinary myoglobin clearance. Unlike littermate controls, the megalin-deficient mice also did not develop progressive GFR decline and persistent new proteinuria. Administration of the pharmacologic megalin inhibitor cilastatin to wild-type mice recapitulated the renoprotective effects of megalin deletion. This cilastatin-mediated renoprotective effect was dependent on megalin. Cilastatin administration caused selective proteinuria and inhibition of tubular myoglobin uptake similar to that caused by megalin deletion. CONCLUSIONS: We conclude that megalin plays a critical role in rhabdomyolysis-induced AKI, and megalin interference and inhibition ameliorate rhabdomyolysis-induced AKI. Further investigation of megalin inhibition may inform translational investigation of a novel potential therapy.
BACKGROUND: Rhabdomyolysis, the destruction of skeletal muscle, is a significant cause of AKI and death in the context of natural disaster and armed conflict. Rhabdomyolysis may also initiate CKD. Development of specific pharmacologic therapy is desirable because supportive care is nearly impossible in austere environments. Myoglobin, the principal cause of rhabdomyolysis-related AKI, undergoes megalin-mediated endocytosis in proximal tubule cells, a process that specifically injures these cells. METHODS: To investigate whether megalin is protective in a mouse model of rhabdomyolysis-induced AKI, we used male C57BL/6 mice and mice (14-32 weeks old) with proximal tubule-specific deletion of megalin. We used a well-characterized rhabdomyolysis model, injection of 50% glycerol in normal saline preceded by water deprivation. RESULTS: Inducible proximal tubule-specific deletion of megalin was highly protective in this mouse model of rhabdomyolysis-induced AKI. The megalin knockout mice demonstrated preserved GFR, reduced proximal tubule injury (as indicated by kidney injury molecule-1), and reduced renal apoptosis 24 hours after injury. These effects were accompanied by increased urinary myoglobin clearance. Unlike littermate controls, the megalin-deficient mice also did not develop progressive GFR decline and persistent new proteinuria. Administration of the pharmacologic megalin inhibitor cilastatin to wild-type mice recapitulated the renoprotective effects of megalin deletion. This cilastatin-mediated renoprotective effect was dependent on megalin. Cilastatin administration caused selective proteinuria and inhibition of tubular myoglobin uptake similar to that caused by megalin deletion. CONCLUSIONS: We conclude that megalin plays a critical role in rhabdomyolysis-induced AKI, and megalin interference and inhibition ameliorate rhabdomyolysis-induced AKI. Further investigation of megalin inhibition may inform translational investigation of a novel potential therapy.
Authors: Jakub Gburek; Pierre J Verroust; Thomas E Willnow; John C Fyfe; Wojciech Nowacki; Christian Jacobsen; Søren K Moestrup; Erik I Christensen Journal: J Am Soc Nephrol Date: 2002-02 Impact factor: 10.121
Authors: May A Beydoun; Salman M Tajuddin; Greg A Dore; Jose-Atilio Canas; Hind A Beydoun; Michele K Evans; Alan B Zonderman Journal: J Nutr Date: 2017-04-26 Impact factor: 4.798
Authors: Johannes Schindelin; Ignacio Arganda-Carreras; Erwin Frise; Verena Kaynig; Mark Longair; Tobias Pietzsch; Stephan Preibisch; Curtis Rueden; Stephan Saalfeld; Benjamin Schmid; Jean-Yves Tinevez; Daniel James White; Volker Hartenstein; Kevin Eliceiri; Pavel Tomancak; Albert Cardona Journal: Nat Methods Date: 2012-06-28 Impact factor: 28.547
Authors: E I Christensen; J O Moskaug; H Vorum; C Jacobsen; T E Gundersen; A Nykjaer; R Blomhoff; T E Willnow; S K Moestrup Journal: J Am Soc Nephrol Date: 1999-04 Impact factor: 10.121
Authors: Rumie Wakasaki; Katsuyuki Matsushita; Kirsti Golgotiu; Sharon Anderson; Mahaba B Eiwaz; Daniel J Orton; Sang Jun Han; H Thomas Lee; Richard D Smith; Karin D Rodland; Paul D Piehowski; Michael P Hutchens Journal: JCI Insight Date: 2019-02-21
Authors: L Riedemann; C Lanvers; D Deuster; U Peters; J Boos; H Jürgens; A am Zehnhoff-Dinnesen Journal: Pharmacogenomics J Date: 2007-04-24 Impact factor: 3.550
Authors: Franziska Theilig; Wilhelm Kriz; Timo Jerichow; Petra Schrade; Brunhilde Hähnel; Thomas Willnow; Michel Le Hir; Sebastian Bachmann Journal: J Am Soc Nephrol Date: 2007-04-25 Impact factor: 10.121
Authors: Arthur Lau; Jennifer J Rahn; Mona Chappellaz; Hyunjae Chung; Hallgrimur Benediktsson; Dominique Bihan; Anne von Mässenhausen; Andreas Linkermann; Craig N Jenne; Stephen M Robbins; Donna L Senger; Ian A Lewis; Justin Chun; Daniel A Muruve Journal: Sci Adv Date: 2022-02-02 Impact factor: 14.136